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Abstract
Background: Claims made about the effects of treatments are very common in the media and in the population
more generally. The ability of individuals to understand and assess such claims can affect their decisions and health
outcomes. Many people in both low- and high-income countries have inadequate aptitude to assess information
about the effects of treatments. As part of the Informed Healthcare Choices project, we have prepared a series of
podcast episodes to help improve people’s ability to assess claims made about treatment effects. We will evaluate
the effect of the Informed Healthcare Choices podcast on people’s ability to assess claims made about the benefits
and harms of treatments. Our study population will be parents of primary school children in schools with limited
educational and financial resources in Uganda.
Methods: This will be a two-arm, parallel-group, individual-randomised trial. We will randomly allocate consenting
participants who meet the inclusion criteria for the trial to either listen to nine episodes of the Informed Healthcare
Choices podcast (intervention) or to listen to nine typical public service announcements about health issues
(control). Each podcast includes a story about a treatment claim, a message about one key concept that we believe
is important for people to be able to understand to assess treatment claims, an explanation of how that concept
applies to the claim, and a second example illustrating the concept.
We designed the Claim Evaluation Tools to measure people’s ability to apply key concepts related to assessing
claims made about the effects of treatments and making informed health care choices. The Claim Evaluation Tools
that we will use include multiple-choice questions addressing each of the nine concepts covered by the podcast.
Using the Claim Evaluation Tools, we will measure two primary outcomes: (1) the proportion that ‘pass’, based on
an absolute standard and (2) the average score.
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Discussion: As far as we are aware this is the first randomised trial to assess the use of mass media to promote
understanding of the key concepts needed to judge claims made about the effects of treatments.
Trial registration: Pan African Clinical Trials Registry, PACTR201606001676150. Registered on 12 June 2016. http://
www.pactr.org/ATMWeb/appmanager/atm/atmregistry?dar=true&tNo=PACTR201606001676150.
Keywords: Critical thinking, Critical appraisal, Higher order thinking, Meta-cognition, Treatment claims, Health
literacy, Evidence-based health care, EBM teaching resources, Primary school curriculum, Science teaching
Background
The ability of individuals to obtain, process, and
understand basic health information is a crucial
element in making health care choices [1]. Such abil-
ity is often limited in both low- and high-income
countries [2, 3]. Studies have revealed limited ability
among patients, their caregivers and the public to as-
sess the benefits and safety of treatments, and poor
understanding of informed consent [4, 5], random al-
location [6], risks [7, 8], and drug approval [9]. Some
studies have found surprisingly low levels of know-
ledge of evidence-based medicine principles among
health workers [10–12].
A poor understanding of health care evidence, and
inadequate ability to recognise claims made about the
effects of health care, can increase or diminish the will-
ingness of individuals to seek care or participate in re-
search. It may raise expectations (sometimes falsely),
may dash hopes, or may provoke alarm (sometimes
unnecessarily). It can result in low uptake of effective
interventions, and inappropriate utilisation of health
services [13]. It can also create communication barriers
between health workers and patients [14, 15] and in-
crease the costs of care [16, 17]. Despite these prob-
lems, there is only a handful of open-access tools to
educate people to appraise information about the bene-
fits and safety of treatments [18–22], or tools that sim-
plify the interpretation of research information [23, 24].
To fill this gap, we have developed the Informed
Healthcare Choices (IHC) resources which we are cur-
rently evaluating.
Improving access to reliable health information in the
mass media – such as the Internet, radio, TV and print
media – has the potential to affect individual health be-
haviours, health care utilisation, health care practices,
and health policy [25, 26]. However, there are substantial
barriers that prevent journalists from improving the sci-
entific quality of their reports [27], and evaluations of
health stories in the media have consistently found
major shortcomings [28–30]. Therefore, users, listeners,
viewers, and readers must be able to appraise the trust-
worthiness of claims in the mass media about the effects
of treatments.
We have identified 32 key concepts that are relevant
to evidence-informed decision-making that people need
to understand and apply to assess the trustworthiness of
claims made about treatment effects [31]. These concepts
are grouped into six domains:
1. Recognising the need for fair comparisons of
treatments
2. Judging whether a comparison of treatments is a fair
comparison
3. Understanding the role of chance
4. Considering all the relevant fair comparisons
5. Understanding the results of fair comparisons of
treatments
6. Judging whether fair comparisons of treatments are
relevant
We have developed an educational podcast (a series
of audio messages) to teach people how to apply nine
of the 32 concepts in judging claims made about the
effects of treatments. We settled for the nine concepts
after a series of user-tests in which we identified some
concepts as being more relevant than others for our
target audience and easier than others for people to
understand [32]. If resources allow, we plan to develop
messages for other concepts, taking account of the les-
sons learned from this trial. The purpose of this ran-
domised trial is, therefore, to evaluate the effects of
this podcast on listeners’ abilities to assess claims
made about the effectiveness and safety of treatments.




To evaluate the effects of the IHC podcast on the ability
of parents of primary school children to assess claims
made about the effects of treatments.
Secondary objectives
1. To evaluate the effects of the IHC podcast on
listeners’ knowledge, attitudes, and intended
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behaviours regarding assessing claims and making
decisions
2. To compare participants’ self-assessed ability to
assess the reliability of claims made about treatment
effects and their objective ability as measured by the
Claim Evaluation Tools




This will be a two-arm, parallel-group, individual-
randomised trial evaluating the impacts of a podcast
series designed to teach concepts of evidence-informed
decision-making to parents of primary school children
in Uganda (Fig. 1).
Setting
The study will be conducted in central Uganda within
the communities in which participants live and work.
Uganda is a landlocked country in East-Central Africa. It
is a multiethnic country with slightly over 70% of the
population aged below 25 years. The country has a life
expectancy at birth of 54.9 years, total fertility rate of 5.9
children, literacy rate of 78.4%, maternal mortality ratio
of 343 per 100,000 live births, and infant mortality rate
of 59 per 1000 live births. It has 0.1 physicians per 1000
people [33].
Study population and random allocation
Our study population will be parents of primary school
children in schools with limited educational and financial
resources. We will draw a sample of parents of children
from schools participating in a cluster-randomised trial of
IHC primary school resources, designed to help primary
school children understand and assess claims made about
treatment effects [34].
All public and private primary schools in the central
region of Uganda will be eligible to participate in the
IHC primary school resources trial. The only exclusions
will be international schools, special needs children’s
schools for the deaf and blind, and schools or classes
that participated in the user-testing and piloting of the
teaching resources. We intend to include at least 120
schools in that trial.
Inclusion and exclusion criteria
Inclusion
 Parents of children attending the schools
participating in the trial of the IHC teaching
resources
 The ability to communicate in the language of the
podcast (English or Luganda)
 Consent to participate in the study
Exclusion
 Being unable to hear
 Not contactable by phone
 Health researchers
 Parents who have participated in the development
and user-testing of the podcast
 Parents of children who participated in the
development and user-testing of the children’s
resources [34]
Sampling technique
We will randomly select at least 30 schools among the
120 participating in the related trial evaluating the ef-
fectiveness of IHC materials designed for primary
school children [34]. This number is informed by find-
ings from our earlier engagements with parents, in
which only about 10 to 20 parents attended meetings
that are not on the usual school programme. About half
of the schools selected will be from the intervention
arm and the other half from the control arm of the
schools participating in the trial evaluating primary
school resources. In each of the selected schools we will
Assessed for eligibility (n=?)





2. Episodes 1 & 2
3. Episodes 3 & 4
4. Episodes 5 & 6
5. Episodes 7 & 8
6. Concluding episode (9)









2. Announcements 1 & 2
3. Announcements 3 & 4
4. Announcements 5 & 6
5. Announcements 7 & 8
6. Summary
7. Outcome measurement 
Analysis: one year post-
intervention (n=?)
Outcome measurement: 
one year post-intervention 
Fig. 1 Study flow chart
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create a list of parents of P.5 children and invite them
to a meeting at the schools. At these meetings we will
provide parents with information about the podcast
trial and seek their consent to participate.
Because parents who attend meetings might be different
than those who do not, we will also make an effort to
reach parents who will not have attended the meetings
through phone calls, where possible.
Parents who accept to participate will be asked to sign
a Consent Form (Additional files 1 and 2) before ran-
domisation to begin their participation in the study.
We will provide information about the trial to partici-
pants in a brochure designed as part of a package invit-
ing parents to participate. This information will also be
available on the participants’ Informed Consent Forms
and will be written in the two most commonly spoken
languages (English and Luganda).
Random allocation
Methods for stratification and randomisation
We will stratify our sample proportionately by the highest
level of education attained (primary school and below,
secondary school, or tertiary education) and whether their
children are in a school that is in the intervention or con-
trol arm of the IHC primary school resources trial.
We will use computer-generated blocked randomisa-
tion. A statistician or other senior researcher at the clinical
trials unit at the College of Health Sciences, Makerere
University who is not a member of the IHC research team
will generate the allocation sequences for the two com-
parison groups. A web-based random number generator
at www.sealedenvelope.com will be used to obtain random
permuted blocks with varying block sizes of 4 and 6, and
equal allocation ratios, both within blocks and within
strata, as shown in Table 1 below.
As shown in Table 1 above, the list will have study
codes that are unique for each participant (column 7),
against which we will attach an ordered array of num-
bers (column 6) spanning the full breadth of our sample
size within each stratum. Each study code will be printed
on a separate opaque envelope.
Methods for allocation concealment
The allocation group corresponding to each study code
will be printed on a separate slip, inserted and sealed in
the corresponding opaque envelope. As shown in the list
above, the first participant to be recruited among those
with primary or no education will have the study code
YL9 on their envelope, inside of which will be a small
note with their allocation group (group A).
To reduce the risk of bias during allocation a separate list
containing the study participant number, and correspond-
ing study code and number within each stratum, will be
generated for each of the three education-level strata (up to
and including primary, at least secondary and tertiary), as
shown in Table 2 below. This list – which will not identify
the study arm – will be given by the statistician to a re-
search assistant who will be in charge of group allocation.
Upon completion of procedures for confirming consent
of a willing participant the research assistant responsible for
recruiting the participant will call the research assistant in
charge of group allocation. The research assistant respon-
sible for allocation will then open the next available enve-
lope in the stratum, corresponding to the participant’s
education level and study arm of the child’s school, to deter-
mine the study group to which the parent will be allocated.
The interventions
Participants in the intervention group will listen to a series
of podcast episodes designed to teach people to assess
Table 1 Excerpt from a sample randomisation lista

















1 4 1 Group A ≤ primary 1 YL9
1 4 2 Group A ≤ primary 2 PX5
1 4 3 Group B ≤ primary 3 JP3
1 4 4 Group B ≤ primary 4 OB2
2 4 1 Group A ≤ primary 5 XD6
2 4 2 Group A ≤ primary 6 JD0
2 4 3 Group B ≤ primary 7 NU5
2 4 4 Group B ≤ primary 8 SS0
3 4 1 Group B ≤ primary 9 SK0
3 4 2 Group A ≤ primary 10 QN4
aList generated from www.sealedenvelope.com






















1 YL9 1 FO4 1 TH4
2 PX5 2 HG6 2 UW0
3 JP3 3 GS3 3 AT5
4 OB2 4 PS9 4 SX4
5 XD6 5 YE9 5 UJ7
6 JD0 6 BH7 6 XD9
7 NU5 7 HN6 7 RJ7
8 SS0 8 TY7 8 CS1
9 SK0 9 DT3 9 BC4
10 QN4 10 FZ1 10 ED1
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claims made about treatment effects (the IHC podcast).
Each episode includes a short story with an example of a
treatment claim, a simple explanation of a concept used to
assess that claim, another example of a claim illustrating
the same concept, and its corresponding explanation. In
each story there is a question about the trustworthiness of
a claim, which is resolved by applying the relevant key
concept. All episodes have a conclusion with a take-home
message emphasising the concept of evidence-informed,
health decision-making. The examples used in the podcast
are for claims made about treatments for health condi-
tions, which are of interest to the target audience, such as
malaria, diarrhoea, and HIV/AIDS. We have also included
claims made about some common practices, such as
contraception, which are of interest to our audience.
The topics and claims were identified from scanning re-
cent mass media reports and interviewing parents [32].
There are eight main episodes in the series covering the
nine core concepts (Table 3). Each episode lasts about
5 min. One of the episodes (episode 1) covers two closely
related key concepts (1.1 and 5.1 in Table 3). Two add-
itional episodes introduce the podcast and summarise the
key messages from the first eight episodes, respectively.
The podcast also has a song (the IHC theme song), sections
of which play at the beginning, in the background and at
the end of the episodes. The lyrics of the song were de-
signed to reinforce the messages of the podcast and focus
on being careful about claims, and the important questions
to ask when we hear claims made about treatment effects.
The final structure, content, presentation of the content in
each episode, and the series as a whole was informed by an
iterative user-centred process of development and user-
testing described in another paper [32]. This process in-
volved consultation with various stakeholders, including
parents in our target audience, on the appropriate content
to be included, and the presentation of this content in each
episode, and in the podcast as a whole [32]. The numbering
in the first column in the table below relates to numbering
of the key concepts in their respective domains, as pre-
sented by Austvoll-Dahlgren et al. [31].
A summary of the concepts contained in each episode
of the podcast is shown in Table 4 below.
Participants in the control group will receive typical pub-
lic service announcements about conditions of interest to
our target audience, including malaria, HIV/AIDS, and
diarrhoea, that have been included in the podcast. These
audio messages are already being aired or have in the recent
past been aired on radio. They are freely available and will
be sourced from radio stations and media houses involved
in disseminating information from the Ministry of Health.
Delivery of the interventions
The interventions will be delivered over a period of 7 to
10 weeks to participants in the communities where they
live or work. At least 20 research assistants will help in
the field recruitment, administration of the intervention,
follow-up of participants in the community, and adminis-
tration of the outcome assessment tool. Each research as-
sistant will be allocated about 25 participants to follow up
through the duration of the study. The research assistants
will visit all their allocated participants every week, deliv-
ering the interventions on portable media players to an
average of four participants per day. In this study setting
this approach is currently the most practical and most re-
liable way of delivering the interventions for this trial.
One-time brief interventions have not been shown to
improve knowledge of evidence-based medicine principles
[35, 36] among health workers. So, as part of our interven-
tion, at every visit we will play a recap of the previous epi-
sodes before playing the new episodes. Each participant
will receive at least one supervised listening session of
every episode, delivered by the research assistants over 7
to 10 weeks. In addition to the messages delivered by the
research assistants, we will provide participants with the
complete podcast on MP3 players, so that they can replay
the episodes at their convenience. For the intervention
group we will start with simpler concepts and gradually
introduce more difficult concepts as the podcast series
progresses, as summarised in Table 5 below. For the con-
trol group we will introduce episodes with health condi-
tions that are similar to those being delivered in the
intervention group at a defined period of time. The timing
of study procedures is summarised in Fig. 2 below.
Outcome assessment
We will use a modified version of the Claim Evaluation
Tools as the outcome measure [37]. The Claim Evalu-
ation Tools consist of multiple-choice questions that as-
sess an individual’s ability to apply 32 concepts that
people need to be able to understand and apply to assess
the validity of treatment claims and to make informed
health care choices. In addition, it includes questions
that assess intended behaviours, self-efficacy, attitudes,
and satisfaction. Development of the Claim Evaluation
Tools has been based on extensive qualitative and quan-
titative feedback from methodological experts, health
professionals, teachers, and members of the public. We
have conducted psychometric testing and Rasch analysis
with a diverse sample of 1000 people, including P.5 chil-
dren exposed to pilot versions of the IHC primary
school resources, children who were not exposed, adults
with little or no exposure to the concepts, and adults
who are familiar with the concepts. The evaluation tool
was found to have high reliability (Cronbach’s alpha
0.81), and to be unidimensional (there was no evidence
of subdimensions measuring different traits). Further-
more, there was weak or no dependence between items
(no items were redundant). Results from the pilot revealed
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Table 3 The nine conceptsa included in the IHC podcast
Concepts Explanations Implications
1.1 Treatments may be harmful People often exaggerate the benefits of
treatments and ignore or downplay potential
harms. However, few effective treatments are
100% safe
Always consider the possibility that a treatment
may have harmful effects
1.2 Personal experiences or anecdotes
(stories) are an unreliable basis for
assessing the effects of most treatments
People often believe that improvements in a
health problem (e.g. recovery from a disease)
were due to having received a treatment.
Similarly, they might believe that an undesirable
health outcome was due to having received a
treatment. However, the fact that an individual
got better after receiving a treatment does not
mean that the treatment caused the
improvement, or that others receiving the same
treatment will also improve. The improvement (or
undesirable health outcome) might have
occurred even without treatment
Claims made about the effects of a treatment
may be misleading if they are based on stories
about how a treatment helped individual people,
or if those stories attribute improvements to
treatments that have not been assessed in
systematic reviews of fair comparisons
1.3 A treatment outcome may be associated
with a treatment, but not caused by the
treatment
The fact that a treatment outcome (i.e. a potential
benefit or harm) is associated with a treatment
does not mean that the treatment caused the
outcome. For example, people who seek and
receive a treatment may be healthier and have
better living conditions than those who do not
seek and receive the treatment. Therefore, people
receiving the treatment might appear to benefit
from the treatment, but the difference in
outcomes could be because of their being
healthier and having better living conditions,
rather than because of the treatment
Unless other reasons for an association between
an outcome and a treatment have been ruled out
by a fair comparison, do not assume that the
outcome was caused by the treatment
1.4 Widely used treatments or treatments
that have been used for a long time are
not necessarily beneficial or safe
Treatments that have not been properly
evaluated but are widely used or have been used
for a long time are often assumed to work.
Sometimes, however, they may be unsafe or of
doubtful benefit
Do not assume that treatments are beneficial or
safe simply because they are widely used or have
been used for a long time, unless this has been
shown in systematic reviews of fair comparisons
of treatments
1.6 Opinions of experts or authorities do not
alone provide a reliable basis for deciding
on the benefits and harms of treatments
Physicians, researchers, patient organisations, and
other authorities often disagree about the effects
of treatments. This may be because their opinions
are not always based on systematic reviews of fair
comparisons of treatments
Do not rely on the opinions of experts or other
authorities about the effects of treatments, unless
they clearly base their opinions on the findings of
systematic reviews of fair comparisons of
treatments
2.1 Evaluating the effects of treatments
requires appropriate comparisons
If a treatment is not compared to something else,
it is not possible to know what would happen
without the treatment, so it is difficult to attribute
outcomes to the treatment
Always ask what the comparisons are when
considering claims made about the effects of
treatments. Claims that are not based on
appropriate comparisons are not reliable
2.2 Apart from the treatments being
compared, the comparison groups need
to be similar (i.e. ‘like needs to be
compared with like’)
If people in the treatment comparison groups
differ in ways other than the treatments being
compared, the apparent effects of the treatments
might reflect those differences rather than actual
treatment effects. Differences in the characteristics
of the people in the comparison groups might
result in estimates of treatment effects that
appear either larger or smaller than they actually
are. A method, such as allocating people to
different treatments by assigning them random
numbers (the equivalent of flipping a coin), is the
best way to ensure that the groups being
compared are similar in terms of both measured
and unmeasured characteristics
Be cautious about relying on the results of
nonrandomised treatment comparisons (for
example, if the people being compared chose
which treatment they received). Be particularly
cautious when you cannot be confident that the
characteristics of the comparison groups were
similar. If people were not randomly allocated to
treatment comparison groups, ask if there were
important differences between the groups that
might have resulted in the estimates of treatment
effects appearing either larger or smaller than
they actually are
4.1 The results of single comparisons of
treatments can be misleading
A single comparison of treatments rarely provides
conclusive evidence and results are often
available from other comparisons of the same
treatments. These other comparisons may have
different results or may help to provide more
reliable and precise estimates of the effects of
treatments
The results of single comparisons of treatments
can be misleading
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that parents in the intervention group performed slightly
better compared with those in the control group. Many of
the participants in the pilot preferred Luganda to English
and had difficulty reading the questions in English.
After removing some questions, we modified the
remaining questions that did not perform well according
to the Rasch analysis, and revised and simplified the text
where needed. The items were also translated into Lu-
ganda and adapted for audio administration. In the sec-
ond psychometric testing, the Claim Evaluation Tools
were administrated to a similar sample as described in
the first psychometric test, but approximately half of
the sample received the items as a written questionnaire
in English and the other half received the Luganda audio
versions. The results of this test suggested that the items
administered in English performed very well according to
the Rasch model, and with high reliability. Furthermore,
the items were also less difficult than what was found in
the first psychometric testing before the revisions. The re-
sults also suggested that the Luganda versions of items
had evidence of under-discrimination and differential item
functioning in seven out of 29 items. These items were re-
vised to improve fit to the Rasch model.
Based on these two psychometric tests, a selection of
18 multiple-choice items addressing the nine concepts
that the IHC podcast covers will be used (Additional file 3).
Each key concept is evaluated by two items. We chose
items with high reliability (fit to the Rasch model) and
those with an appropriate difficulty level.
Parents in both arms of the trial will complete the
questionnaires after they have listened to the podcast or
public service announcements. Research assistants will
deliver the questionnaires, ensuring that the parents
have adequate time to answer the questions and ensure
that the questionnaires have been completed fully.
Absolute standard (for passing scores)
We will use an absolute (criterion referenced) standard to
set a passing score for the version of the Claim Evaluation
Tools that we will use, i.e. based on how much the parents
know and are able to apply. Parents will be counted as
‘passing’ or ‘failing’ depending on whether they meet a
specified criterion. We used a combination of Nedelsky’s
[38] and Angoff ’s [39] methods to determine the criterion,
which is a cut-off for a passing score, as described in
Additional file 4. In addition, we determined a second cut-
off for a score that indicates mastery of the nine concepts,
using the same methods, as described in Additional file 4.
The criterion for passing is a minimum of 11 out of 18
questions answered correctly. The criterion for mastery is
a minimum of 15 out of 18 questions answered correctly.
Primary outcomes
1. The difference between the intervention and control
groups in the proportion of participants with a passing
score
2. The mean difference in the score (number of
correct answers) for all of the questions that assess
their ability to apply the nine concepts that are
included in the IHC podcast
Secondary outcomes
1. The difference between the intervention and control
groups in the proportion of parents with a score
indicating mastery of the concepts (see above)
2. The difference between the intervention and control
groups for each concept
3. Differences in attitudes and intended behaviours
between the two groups
The intervention and control groups will complete the
Claim Evaluation Tools after listening to all of the IHC epi-
sodes or public service announcements, respectively. We
will evaluate the effects of the IHC podcast series again
after 1 year, using the same outcome measures. We will try
to locate participants who will have moved from their ori-
ginal residence or work place and document those who are
lost to follow-up, as well as the reasons, where possible.
Blinding
Because of the nature of the intervention, the research
assistants who will deliver the intervention, the principle
Table 3 The nine conceptsa included in the IHC podcast (Continued)
5.1 Treatments usually have beneficial and
harmful effects
Because treatments can have harmful effects as
well as beneficial effects, decisions should be
informed by the balance between the benefits
and harms of treatments. Costs also need to be
considered
Always consider the trade-offs between the po-
tential benefits of treatments and the potential
harms and costs of treatments
aFrom Austvoll-Dahlgren et al. [31]
Table 4 The conceptsa contained in each episode of the podcast
Episode 1 2 3 4 5 6 7 8
Concepta 1.1 + 5.1 2.1 1.2 1.3 1.4 1.6 2.2 4.1
aSee Table 3 for the full description of the concepts and their implications
Table 5 Sequence of delivery of the episodes of the podcast
Week/Visit 1 2 3 4 5 6 7
Episode Intro 1 + 2 3 + 4 5 + 6 7 + 8 9 Evaluationa
aStudy evaluation tool (Additional file 3).
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investigator supervising them, and the participants in the
study will not be blinded. The statistician who will analyse
the study results will not be told which group is the inter-
vention group until after the analyses are completed.
To ensure uniform performance in delivery of the
intervention and assessment of outcomes, all study staff
will receive joint training before the start of the trial and
will receive refresher training in the course of the trial.
STUDY PERIOD
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Fig. 2 Schedule of enrolment, interventions, and assessments
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We will have standard operating procedures to guide in-
teractions with participants.
Data collection and management
Postrecruitment retention strategies
We will maintain a database of participants’ contact
details and maps to their homes to enable follow-up.
The research assistants will keep a study logbook and
use a progress tracking checklist (Tables 6 and 7) to
keep track of their progress and note any problems with
follow-up of participants. We will discuss these problems
and ways of addressing them and preventing loss to
follow-up at weekly meetings.
Data collection and management
We will use paper questionnaires for the outcome as-
sessment and we will collect baseline sociodemographic
characteristics using a paper form. For participants who
prefer listening to the Luganda version of the podcast
but are unable to read Luganda we will use an
interviewer-administered, standardised Luganda audio
version of the evaluation tool. A research assistant will
enter their responses to the audio evaluation tool on a
paper questionnaire. To reduce any wrong entries and
missing values the research assistants will check the
questionnaires for completeness and for unclear re-
sponses immediately after completion. We will use
Epidata version 3 software [40] to enter all data from
the paper questionnaires and convert them into an
electronic dataset. To reduce errors during data entry
we will double-enter all the data. All data entrants will
be trained on the meaning of variables and how they
should be entered into the database. Questions that re-
main unanswered will be scored as ‘wrong’. The lead
investigator will double-check the entries.
All copies of Consent Forms will be kept separate
from the completed questionnaires and baseline char-
acteristics of the participants. Both signed Informed
Consent Forms and completed questionnaires will be
kept under lock and key. All electronic data will be
password-protected and kept on a separate hard disc,
which will be backed up every week to prevent data
loss. The hard discs will also be kept under lock
and key and access will be restricted to study
investigators.
Trial progress reports will be compiled by the study
team and submitted to the regulatory bodies (Uganda
National Council for Science and Technology and
School of Medicine Research and Ethics Committee
(SOMREC), Makerere University College of Health
Sciences), in accordance with their respective guidelines.
Final project reports (including trial reports) will be com-
piled by the study staff and submitted to the relevant bod-
ies (Research Ethics Committees (RECs) and funders), as
per their requirements.
Analysis
We will present participants’ age, sex, and highest level
of education attained as frequencies and proportions.
For the primary and secondary outcomes, we will
use fixed-effect models with the stratification variable
(education) modelled as a fixed effect, using logistic
regression for dichotomous outcomes, linear regres-
sion for continuous outcomes and Poisson regression
for count outcomes. For the questions that assess ap-
plied knowledge or understanding, missing values will
be counted as ‘wrong’ answers.
We will report the proportion (for dichotomous out-
comes), mean and standard deviation (for continuous
outcomes), or median and interquartile range (for count
outcomes) in each group, the estimated difference, the
estimated confidence interval for the difference, and
the P value for the difference between groups from the
statistical model for each of the primary and secondary
outcomes. For attitudes and intended behaviours
(Additional file 3), we will dichotomise each outcome
by combining, for example, ‘very unlikely’ with ‘unlikely’
and as ‘likely’ with ‘very likely’; and we will report the
proportion in each of the four categories.
Subgroup and exploratory analyses
Education might affect people’s ability to understand
and apply the concepts and to answer questions in the
Claim Evaluation Tools. We will explore whether there
are differences in the effects of the intervention for par-
ticipants with primary school education versus second-
ary school education versus tertiary education. We will
conduct tests for interaction for the primary outcomes,
and we will use published guidelines to interpret the
results of these subgroup analyses [41], using the models
described above.
Table 6 Study log for monitoring progress of the intervention for each study participant
Study number _____________ Date enrolled ____________ Study arm _____
Visit number Date contacted by phone Date seen Date intervention was administered Observations and comments for study visit
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The children of all participants will be participating in a
parallel trial evaluating the effects of IHC teaching re-
sources, designed to teach P.5 school children concepts
that they need to understand and apply to assess treatment
claims [34], but only half of them will be receiving the IHC
teaching resources. By testing for interaction between IHC
teaching resources and the podcast in the statistical models
described above we will evaluate whether the combination
of the podcast and the IHC teaching resources improves
outcomes among parents, compared to the podcast alone.
Sample size
We used the method described by Donner [42] to calcu-
late the sample size, based on calculation of odds ratios.
The smallest difference between the intervention and
control groups that we want to be able to detect in the
proportion of respondents with a passing score is 10
percentage points. Assuming that 10% of the control
group will achieve a passing score (a conservative esti-
mate, based on data from the pilot [32], power of 0.90, a
two-sided P value of 0.05, we estimate that 397 partici-
pants will be needed to be able to detect an improvement
of 10% in the intervention group. Studies of the effects of
drug fact boxes and a primer to help people understand
risk suggest that this is likely to be an adequate sample
size [25, 26]. Allowing for a 20% loss to follow-up gives us
a sample size of 497 participants. More specific informa-
tion about the trial and this protocol is summarised in the
SPIRIT checklist (Additional file 5).
Safety monitoring and adverse events
The National Council of Science and Technology in
Uganda has given this study a very low rating for risk to
participants. Nonetheless, we will monitor unexpected
adverse events and problems that might arise.
Stakeholder involvement
We have engaged health researchers, journalists, other
media and communications practitioners, teachers, and
the general public in developing, revising, piloting, and
user-testing the podcast [32].
Reporting, dissemination and notification of results
Authorship of publications arising from this study will be
according to contribution. Publications and the resources
will be open access, allowing free noncommercial use, dis-
tribution, reproduction and further development of the
work provided the source is properly cited. We will ac-
knowledge all staff participating in the trial.
The results of this trial will be publicised through a var-
iety of channels. All of the resources will be made available
on the IHC project and Testing Treatments interactive
websites, and through the Critical Appraisal Resource Li-
brary (CARL). They will be disseminated internationally by
the IHC project team and through members of our inter-
national advisory group, the Cochrane Collaboration
(www.cochrane.org), the Evidence-informed Policy Net-
work (www.evipnet.org), the WHO, the Campbell Collabor-
ation (www.campbellcollaboration.org), and other relevant
networks and organisations.
Discussion
To the best of our knowledge this is the first randomised
trial to assess the use of mass media to promote under-
standing of the key concepts that are essential to im-
proving people’s ability to critically assess claims made
about the effects of treatments. A basic understanding of
these concepts is envisaged to improve critical assess-
ment of things that people say about what effects treat-
ments might have if, or when, we use them.
In this context the factors, which may facilitate or
hinder people’s understanding of information on asses-
sing claims made about treatment effects, are largely
unknown. Therefore, we plan to conduct a process
evaluation to explore these and any other issues that
might explain why the intervention worked or did not
work as expected. We shall use this information to im-
prove the design and administration of future interven-
tions of this nature.
It is expected that recruitment of parents will be slow
and follow-up may be difficult. From earlier pilots done in
this context, very few parents attended parents’ meetings
at schools and those who did arrived very late. The major-
ity of our study participants are very likely to be women
since mothers tend to be the ones who commonly attend
parents’ meetings. It is not known how representative
these will be of our intended study population. In our
process evaluation we shall explore reasons why, if this
turns out to be the case, and reasons for choosing not to
participate among those who decline to consent.
Table 7 Sample study procedures checklist for all participants
Research assistant: ________________ Contacts________ Date started_________
Participant particulars Dates for study procedures and visits
ID Name Group Contacts Consent Intro 1–2 3–4 5–6 7–8 9 Claim Evaluation Tool
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Trial status
This study is currently recruiting participants.
Additional files
Additional file 1: Consent form Podcast trial English version. (DOCX 27 kb)
Additional file 2: Consent form Podcast trial Luganda translated
version. (DOCX 29 kb)
Additional file 3: The CLAIM Evaluation Tools. (ZIP 1007 kb)
Additional file 4: Setting a standard for the “Claim 12” and “Claim 9”.
(DOCX 28 kb)
Additional file 5: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (DOC 122 kb)
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